Drug intelligence / Profile preview

caffeine + ephedrine + leptin A-200

Development stage: Unknown
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous

Overview

A combination drug consisting of caffeine, ephedrine, and leptin A-200 (recombinant methionyl human Fc-leptin) that was studied for weight loss and reduction of visceral fat mass. The combination was evaluated in a 24-week randomized clinical trial. While caffeine/ephedrine alone and in combination with leptin A-200 showed significant weight loss effects, leptin A-200 alone was not effective. Only the combination treatment significantly reduced visceral fat mass.

Other names: leptin A-200 + caffeine/ephedrineLCE

Targets

ADORA2A (Adenosine A₂A Receptor)LEPR (Leptin receptor)ADRB1 (β1)PDE (Phosphodiesterase family)ADORA1 (Adenosine receptor A1 subtype)ADRA1A (α1A)

Beyond the preview

Go deeper on caffeine + ephedrine + leptin A-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on caffeine + ephedrine + leptin A-200.

Explore the full profile